New Results
Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates
View ORCID ProfileFernanda P. Pons-Faudoa, Antons Sizovs, Kathryn A. Shelton, Zoha Momin, Lane R. Bushman, Jiaqiong Xu, View ORCID ProfileCorrine Ying Xuan Chua, View ORCID ProfileJoan E. Nichols, Trevor Hawkins, View ORCID ProfileJames F. Rooney, Mark A. Marzinke, View ORCID ProfileJason T. Kimata, Peter L. Anderson, Pramod N. Nehete, Roberto C. Arduino, Mauro Ferrari, K. Jagannadha Sastry, View ORCID ProfileAlessandro Grattoni
doi: https://doi.org/10.1101/2020.05.13.091694
Fernanda P. Pons-Faudoa
1Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
2Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, NL, Mexico
Antons Sizovs
1Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
Kathryn A. Shelton
3Department of Comparative Medicine, Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center, Bastrop, TX 78602, USA
Zoha Momin
4Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
Lane R. Bushman
5Deparment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, CO 80045, USA
Jiaqiong Xu
6Center for Outcomes Research and DeBakey Heart and Vascular Center, Houston Methodist Research Institute, Houston, TX 77030, USA
7Weill Medical College of Cornell University, New York, NY 10065, USA
Corrine Ying Xuan Chua
1Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
Joan E. Nichols
8Division of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA
Trevor Hawkins
9Gilead Sciences, Inc., Foster City, CA 94404, USA
James F. Rooney
9Gilead Sciences, Inc., Foster City, CA 94404, USA
Mark A. Marzinke
10Departments of Pathology and Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
Jason T. Kimata
4Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
Peter L. Anderson
5Deparment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, CO 80045, USA
Pramod N. Nehete
3Department of Comparative Medicine, Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center, Bastrop, TX 78602, USA
11The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA
Roberto C. Arduino
12Division of Infectious Diseases, Department of Internal Medicine, McGovern Medical School at The University of Texas Health Science Center, Houston, TX 77030, USA
Mauro Ferrari
13School of Pharmacy, University of Washington, Seattle, WA 98195, USA
K. Jagannadha Sastry
3Department of Comparative Medicine, Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center, Bastrop, TX 78602, USA
14Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Alessandro Grattoni
1Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
15Department of Surgery, Houston Methodist Research Institute, Houston, TX 77030, USA
16Department of Radiation Oncology, Houston Methodist Research Institute, Houston, TX 77030, USA
Article usage
Posted July 17, 2020.
Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates
Fernanda P. Pons-Faudoa, Antons Sizovs, Kathryn A. Shelton, Zoha Momin, Lane R. Bushman, Jiaqiong Xu, Corrine Ying Xuan Chua, Joan E. Nichols, Trevor Hawkins, James F. Rooney, Mark A. Marzinke, Jason T. Kimata, Peter L. Anderson, Pramod N. Nehete, Roberto C. Arduino, Mauro Ferrari, K. Jagannadha Sastry, Alessandro Grattoni
bioRxiv 2020.05.13.091694; doi: https://doi.org/10.1101/2020.05.13.091694
Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates
Fernanda P. Pons-Faudoa, Antons Sizovs, Kathryn A. Shelton, Zoha Momin, Lane R. Bushman, Jiaqiong Xu, Corrine Ying Xuan Chua, Joan E. Nichols, Trevor Hawkins, James F. Rooney, Mark A. Marzinke, Jason T. Kimata, Peter L. Anderson, Pramod N. Nehete, Roberto C. Arduino, Mauro Ferrari, K. Jagannadha Sastry, Alessandro Grattoni
bioRxiv 2020.05.13.091694; doi: https://doi.org/10.1101/2020.05.13.091694
Subject Area
Subject Areas
- Biochemistry (11703)
- Bioengineering (8718)
- Bioinformatics (29127)
- Biophysics (14930)
- Cancer Biology (12048)
- Cell Biology (17353)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14143)
- Epidemiology (2067)
- Evolutionary Biology (18266)
- Genetics (12219)
- Genomics (16765)
- Immunology (11841)
- Microbiology (28003)
- Molecular Biology (11551)
- Neuroscience (60804)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3229)
- Physiology (4939)
- Plant Biology (10383)
- Synthetic Biology (2877)
- Systems Biology (7333)
- Zoology (1642)